The Medacta Quadra-P Anteverted Study

计划入组 300 人 · 首次发布于 2022 年 7 月 15 日

Increased Femoral Anteversion and Physical Performance

计划入组 44 人 · 首次发布于 2023 年 5 月 31 日

"Evaluation of Postural Control in Children With Increased Femoral Anteversion"

计划入组 32 人 · 首次发布于 2019 年 11 月 29 日

Prostate Cancer(Antev)

Acute Urinary Retention(Antev)

Nicaraven

C₁₅H₁₆N₄O₂

Antev Ltd.

United Kingdom

Medicus Pharma to Acquire Antev for $75 Million, Gaining Novel GnRH Antagonist for Prostate Conditions

FDA Clears Phase 2b Trial of Teverelix for Advanced Prostate Cancer Patients with High Cardiovascular Risk

Medicus Pharma Appoints Carolyn Bonner as CFO While Advancing Multiple Clinical Programs